Home > Keywords > Thématique > Science

Science

Articles

  • TIDES Asia, March 2-5 2021 - 100% Virtual
    4 March 2021, by Elodie DORMES

    Guillaume JACQUOT PharmD, PhD, will present last company results on extra-hepatic delivery of oligonucleotides.

  • Society for the study of Blood-Brain interfaces SEISC 2019 congres
    27 November 2019, by Elodie DORMES

    Stéphane GIRARD will present iPS cell-derived model of the human blood-brain-barrier on Friday 15, Nov Session 1 of the Society for the study of Blood-Brain interfaces SEISC 2019 congres in Paris

  • Vect-Horus will join the Single-Domain Antibodies Summit
    14 September 2023, by Emmanuelle BETTENDORF

    Vect-Horus Vector Discovery Team will attend the Single Domain Antibodies Summit that will be held in Paris from 18th to 20th of September 2023.
    Interesting sessions are planned and Vect-Horus will attend the one dedicated to “Single domain Antibodies engineering and structure” and of course “Single domain Antibodies in neurobiology”.
    We look forward to discussing with the scientific community attending this meeting and sharing with them our last advances in the use of nanobodies as (…)

  • Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by Vect-Horus
    28 January 2019, by Jonathan NOWAK

    Two groups of the Institute of Hematology, Huazhong University in Wuhan and the Key Laboratory of Smart Drug Delivery, Fudan University in Shanghai, well known and specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma, show evidence in mice (Zhang et al., 2013, Biomaterials) of nanoparticle targeting to the brain and glioblastoma with therapeutic benefit, with one of the peptide vectors described by VECT-HORUS in Malcor et al. (2012, J Med Chem).

  • Vect-Horus strengthens its scientific advisory board with the appointment of Frédéric MATONTI
    16 May 2022, by Elodie DORMES

    Vect-Horus extends its Scientific Advisory Board with the expertise of Frédéric Matonti, a Leading Ophthalmology Specialist.

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)

  • Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
    8 September 2023, by Emmanuelle BETTENDORF

    On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)” will be given Sunday, September 10th between 4:55 PM and 5:05 PM at the Hall E2 by Izabela Tworowska.
    Come and take the opportunity to meet and discuss with Vect-Horus on September 9-13, 2023 in Vienna!
    Our #Oncology team, Cedric (…)

  • Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
    15 May 2024, by Emmanuelle BETTENDORF

    The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
    The study showed that these vectors have the potential to improve delivery of medication to the (…)

  • ECMED EU-GliaPhD international conference in MALTA
    28 January 2019, by Jonathan NOWAK

    Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel Khrestchatisky will give a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.

  • Vect-Horus will present at Delivery of Macromolecules, June 8, 2022
    30 May 2022, by Elodie DORMES

    Guillaume JACQUOT, Head of Intracellular Trafficking & Translational Research, will give a talk on this occasion.